Akorn (NASDAQ:AKRX) will report earnings before markets open on Tuesday, May 7th. Akorn, Inc. develops, manufactures, and markets ophthalmic and injectable pharmaceutical products. The Company sells various diagnostic and therapeutic pharmaceutical products focused primarily on ophthalmology, anesthesia, antidotes, and rheumatology. Akorn also markets ophthalmic surgical instruments and other supplies, and provides contract manufacturing for third parties.
Here is your Cheat Sheet to Akorn Earnings:
Earnings Expectations: Analysts expect earnings of $0.14 per share on revenues of $74.07 million. Currently, the company’s P/E ratio stands at 45.91.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.16 to a profit $0.15. For the current year, the average estimate is a profit of $0.62, which is the same as the estimate ninety days ago.
Here’s how Akorn has been performing on an annual basis:
|Revenue ($) in millions||93.60||75.89||86.41||136.92||256.16|
|Diluted EPS ($)||-0.09||-0.28||0.22||0.41||0.32|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||42.62||51.72||63.29||69.63||71.52|
|Diluted EPS ($)||0.0546||0.03||0.09||0.12||0.0796|
Akorn has beat analyst estimates 3 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)